PriceTargets.com logo

Teleflex - TFX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $273.38
  • Forecasted Upside: 16.41%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$234.84 As of 06/2/2023 12:51 PM ET
▲ +1.07 (0.46%)

This chart shows the closing price for TFX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teleflex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TFX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TFX

Analyst Price Target is $273.38
▲ +16.41% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Teleflex in the last 3 months. The average price target is $273.38, with a high forecast of $330.00 and a low forecast of $210.00. The average price target represents a 16.41% upside from the last price of $234.84.

This chart shows the closing price for TFX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Teleflex. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/4/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/2/2023

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/30/2023CL KingInitiated CoverageBuy$293.00Low
4/26/2023Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
4/18/2023MizuhoBoost Target$220.00 ➝ $250.00Low
4/17/2023Truist FinancialBoost TargetHold$250.00 ➝ $264.00Low
3/30/2023JMP SecuritiesReiterated RatingMarket Outperform$330.00Low
2/27/2023Truist FinancialLower TargetHold$260.00 ➝ $250.00Low
2/24/2023Needham & Company LLCReiterated RatingBuy$291.00Low
2/24/2023Raymond JamesBoost TargetOutperform$231.00 ➝ $259.00Low
1/31/2023Truist FinancialLower TargetHold$272.00 ➝ $260.00Low
1/6/2023Morgan StanleyBoost TargetEqual Weight$236.00 ➝ $280.00Low
12/28/2022StephensBoost TargetOverweight$280.00 ➝ $295.00Low
12/20/2022Truist FinancialBoost TargetHold$225.00 ➝ $272.00Low
10/28/2022Raymond JamesLower TargetOutperform$266.00 ➝ $231.00Low
10/28/2022Royal Bank of CanadaLower TargetOutperform$342.00 ➝ $308.00Low
10/28/2022StephensLower TargetOverweight$305.00 ➝ $280.00Low
10/28/2022Wells Fargo & CompanyLower TargetEqual Weight$248.00 ➝ $229.00Low
10/28/2022Truist FinancialBoost TargetHold$220.00 ➝ $225.00Low
10/28/2022JMP SecuritiesLower TargetMarket Outperform$370.00 ➝ $330.00Low
10/27/2022Piper SandlerLower Target$265.00 ➝ $245.00Low
10/26/2022MizuhoInitiated CoverageNeutral$220.00Low
10/13/2022StephensInitiated CoverageOverweight$305.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageHold$210.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$278.00 ➝ $236.00Low
9/22/2022Truist FinancialLower TargetHold$265.00 ➝ $241.00Low
7/29/2022Morgan StanleyLower TargetEqual Weight$300.00 ➝ $278.00Low
7/29/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$248.00Low
7/28/2022Piper SandlerLower Target$295.00 ➝ $265.00Low
7/22/2022Truist FinancialLower Target$270.00Low
7/15/2022Morgan StanleyLower TargetEqual Weight$343.00 ➝ $300.00Low
7/5/2022Wolfe ResearchInitiated CoverageOutperform$300.00N/A
5/23/2022Truist FinancialLower TargetHold$340.00 ➝ $317.00Low
5/23/2022Royal Bank of CanadaLower Target$390.00 ➝ $380.00Low
5/9/2022Bank of AmericaInitiated CoverageNeutral$315.00High
4/29/2022Truist FinancialLower Target$370.00 ➝ $340.00Medium
4/12/2022Truist FinancialInitiated CoverageHold$370.00Medium
2/25/2022Morgan StanleyLower TargetEqual Weight$383.00 ➝ $378.00High
2/24/2022Piper SandlerBoost Target$320.00 ➝ $335.00Medium
2/23/2022Raymond JamesLower TargetOutperform$391.00 ➝ $370.00Low
1/31/2022Needham & Company LLCLower TargetBuy$425.00 ➝ $400.00Low
1/21/2022Piper SandlerLower Target$325.00 ➝ $320.00Low
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$431.00 ➝ $383.00High
1/4/2022Piper SandlerDowngradeOverweight ➝ Neutral$465.00 ➝ $325.00Low
12/13/2021Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$450.00 ➝ $355.00Medium
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$415.00Low
10/29/2021Morgan StanleyLower TargetOverweight$478.00 ➝ $431.00Low
10/29/2021Raymond JamesLower TargetOutperform$440.00 ➝ $391.00Low
10/29/2021JMP SecuritiesLower TargetMarket Outperform$470.00 ➝ $430.00High
9/10/2021Jefferies Financial GroupInitiated CoverageBuy$485.00Medium
9/7/2021Raymond JamesInitiated CoverageBuy$440.00Low
8/2/2021KeyCorpLower TargetOverweight$448.00 ➝ $439.00Low
7/30/2021JMP SecuritiesReiterated RatingMarket OutperformMedium
7/30/2021SVB LeerinkBoost TargetMarket Perform$410.00 ➝ $415.00Low
7/19/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$485.00 ➝ $410.00High
7/9/2021Needham & Company LLCInitiated CoverageBuy$486.00Low
6/2/2021Jefferies Financial GroupReiterated RatingBuy$485.00Medium
5/23/2021SVB LeerinkReiterated RatingBuyLow
4/30/2021Morgan StanleyBoost TargetOverweight$450.00 ➝ $478.00Medium
4/30/2021SVB LeerinkBoost TargetOutperform$475.00 ➝ $485.00Medium
3/12/2021Raymond JamesBoost TargetStrong-Buy$460.00 ➝ $480.00Medium
2/26/2021Raymond JamesBoost TargetStrong-Buy$440.00 ➝ $460.00Low
2/25/2021Piper SandlerReiterated RatingOverweight$405.00 ➝ $465.00Medium
1/27/2021JMP SecuritiesBoost TargetMarket Outperform$375.00 ➝ $440.00Low
1/11/2021Wells Fargo & CompanyBoost TargetOverweight$425.00 ➝ $455.00Medium
1/8/2021KeyCorpBoost TargetOverweight$382.00 ➝ $441.00Medium
1/6/2021Needham & Company LLCBoost TargetBuy$406.00 ➝ $445.00N/A
12/15/2020Morgan StanleyBoost TargetOverweight$375.00 ➝ $450.00Low
12/15/2020UBS GroupBoost TargetBuy$435.00 ➝ $455.00High
12/15/2020SVB LeerinkBoost TargetOutperform$415.00 ➝ $450.00High
12/3/2020Raymond JamesBoost TargetStrong-Buy$400.00 ➝ $440.00Low
11/2/2020KeyCorpUpgradeSector Weight ➝ Overweight$382.00Low
10/30/2020Piper SandlerLower Target$420.00 ➝ $405.00High
10/30/2020Morgan StanleyLower TargetOverweight$400.00 ➝ $375.00Medium
10/30/2020Raymond JamesLower TargetStrong-Buy$440.00 ➝ $400.00High
10/30/2020SVB LeerinkLower TargetOutperform$430.00 ➝ $415.00High
8/28/2020Raymond JamesReiterated RatingBuyMedium
7/31/2020Raymond JamesBoost TargetStrong-Buy$400.00 ➝ $440.00Low
7/31/2020Morgan StanleyBoost TargetOverweight$380.00 ➝ $400.00Medium
6/4/2020SVB LeerinkBoost TargetTop Pick ➝ Outperform$400.00 ➝ $425.00Low
5/1/2020UBS GroupLower TargetBuy$440.00 ➝ $410.00High
5/1/2020JMP SecuritiesLower TargetMarket Outperform$395.00 ➝ $385.00Medium
5/1/2020Wells Fargo & CompanyBoost TargetOverweight$365.00 ➝ $375.00High
5/1/2020Morgan StanleyBoost TargetOverweight$350.00 ➝ $380.00Medium
5/1/2020Raymond JamesBoost TargetStrong-Buy$360.00 ➝ $400.00Medium
5/1/2020Piper SandlerLower TargetOverweight$425.00 ➝ $375.00Medium
4/30/2020Needham & Company LLCReiterated RatingBuy$431.00Medium
4/3/2020Raymond JamesLower TargetStrong-Buy$450.00 ➝ $360.00Low
3/27/2020Morgan StanleyLower TargetOverweight$405.00 ➝ $350.00Medium
3/23/2020StephensLower TargetOverweight$425.00 ➝ $275.00High
2/24/2020BarclaysReiterated RatingHold$365.00 ➝ $378.00Medium
2/21/2020Piper SandlerBoost Target$425.00 ➝ $400.00Low
2/21/2020StephensBoost TargetOverweight$400.00 ➝ $425.00High
2/21/2020Raymond JamesBoost TargetStrong-Buy$415.00 ➝ $450.00High
2/21/2020UBS GroupBoost TargetBuy$430.00 ➝ $440.00High
1/31/2020Needham & Company LLCBoost TargetBuy$408.00 ➝ $423.00High
1/17/2020Wells Fargo & CompanyBoost TargetOverweight$415.00 ➝ $425.00Low
12/18/2019UBS GroupBoost TargetBuy$415.00 ➝ $430.00Medium
12/17/2019Morgan StanleyBoost TargetOverweight$392.00 ➝ $405.00Low
11/1/2019BarclaysSet TargetHold$356.00 ➝ $365.00N/A
10/15/2019Needham & Company LLCSet TargetBuy$403.00Low
10/7/2019Raymond JamesLower TargetStrong-Buy$420.00 ➝ $415.00Low
9/4/2019SVB LeerinkBoost TargetOutperform$395.00 ➝ $405.00Medium
8/5/2019BarclaysBoost TargetEqual Weight$309.00 ➝ $356.00Low
8/5/2019JMP SecuritiesBoost TargetMarket Outperform$325.00 ➝ $395.00Medium
8/2/2019Raymond JamesBoost TargetStrong-Buy$350.00 ➝ $420.00Low
8/2/2019Morgan StanleyBoost TargetOverweight$345.00 ➝ $392.00Low
8/2/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$325.00 ➝ $403.00Low
7/16/2019Morgan StanleyBoost TargetOverweight$320.00 ➝ $345.00Low
6/11/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$345.00Low
4/24/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$325.00Low
4/15/2019BarclaysBoost TargetEqual Weight ➝ Equal Weight$287.00 ➝ $309.00Low
3/27/2019Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$320.00 ➝ $348.00Medium
3/26/2019Needham & Company LLCReiterated RatingBuy$325.00Medium
3/22/2019UBS GroupBoost TargetBuy$350.00Low
2/26/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$305.00 ➝ $315.00Low
2/22/2019BarclaysSet TargetHold$287.00Medium
2/22/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$300.00 ➝ $325.00High
1/2/2019Morgan StanleyBoost TargetOverweight ➝ Overweight$295.00 ➝ $305.00Medium
11/27/2018UBS GroupInitiated CoverageBuy$310.00High
11/2/2018Piper Jaffray CompaniesBoost TargetOverweight$310.00Medium
11/2/2018Needham & Company LLCReiterated RatingBuy$315.00High
10/15/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$266.00Low
9/10/2018Needham & Company LLCUpgradeBuy ➝ Strong-Buy$279.00 ➝ $300.00High
8/3/2018Morgan StanleyLower TargetOverweight ➝ Overweight$310.00 ➝ $295.00Medium
8/3/2018Needham & Company LLCLower TargetBuy$298.00 ➝ $279.00Medium
6/5/2018SVB LeerinkBoost TargetOutperform$309.00 ➝ $317.00Medium
(Data available from 6/2/2018 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2023
  • 11 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2023
  • 19 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 17 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 17 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 17 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023

Current Sentiment

  • 17 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Teleflex logo
Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.
Read More

Today's Range

Now: $234.84
Low: $233.43
High: $235.60

50 Day Range

MA: $253.95
Low: $232.06
High: $274.11

52 Week Range

Now: $234.84
Low: $182.65
High: $289.24

Volume

46,778 shs

Average Volume

313,625 shs

Market Capitalization

$11.01 billion

P/E Ratio

30.62

Dividend Yield

0.58%

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Teleflex?

The following Wall Street sell-side analysts have issued reports on Teleflex in the last twelve months: CL King, Jefferies Financial Group Inc., JMP Securities, Mizuho, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, Stephens, StockNews.com, Truist Financial Co., Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for TFX.

What is the current price target for Teleflex?

13 Wall Street analysts have set twelve-month price targets for Teleflex in the last year. Their average twelve-month price target is $273.38, suggesting a possible upside of 16.4%. JMP Securities has the highest price target set, predicting TFX will reach $330.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $210.00 for Teleflex in the next year.
View the latest price targets for TFX.

What is the current consensus analyst rating for Teleflex?

Teleflex currently has 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TFX will outperform the market and that investors should add to their positions of Teleflex.
View the latest ratings for TFX.

What other companies compete with Teleflex?

Other companies that are similar to Teleflex include Globus Medical, Integra LifeSciences, Insulet, Baxter International and ResMed. Learn More about companies similar to Teleflex.

How do I contact Teleflex's investor relations team?

Teleflex's physical mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company's listed phone number is (610) 225-6800 and its investor relations email address is s[email protected]. The official website for Teleflex is www.teleflex.com. Learn More about contacing Teleflex investor relations.